Everything you want to know about a Resource
PSA has joined NPS MedicineWise and seven other organisations representing pharmacists, specialists, consumers and research experts to form the Targeted Therapies Alliance. The Alliance provides stewardship and direction about the safe and wise use of biological disease-modifying antirheumatic drugs (bDMARDs) and other specialised medicines.
The Pharmaceutical Society of Australia has developed a Screening for cardiovascular disease risk in people living with HIV checklist that can be used to help you screen for risk factors for CVD in your patients living with HIV and guide you to educate and refer those at increased risk to see their doctor for a comprehensive clinical assessment.
The Digital Health Guidelines for Pharmacists describe the professional obligations of pharmacists when interacting with digital health systems in performing their professional clinical roles. These guidelines provide guidance on expected professional practice when using digital health systems, so that pharmacists can provide optimal patient outcomes, while meeting legal and ethical obligations relating to data access and stewardship. The guidelines should be used as a tool to support practice and professional decision making, and ensure that patients’ needs, beliefs and preferences are met. They can be used as an educational resource to inform quality assurance processes, and provide support when resolving legal disputes and ethical dilemmas.
The Digital Health Guidelines for Pharmacists are applicable to all settings in which pharmacists practise and interact with digital health, including settings where the pharmacist does not dispense medicines.
Guidelines produced by the Pharmaceutical Society of Australia (PSA) are not definitive statements of correct procedure but represent agreement by experts in the field. The guidelines do not set a prescribed course of action or a mandatory standard to which pharmacists must adhere.
The guidelines do not provide a technical guide on how to operate digital health systems; rather, they provide guidance on the minimum professional and ethical behaviour for pharmacists when using digital health systems in the delivery of health services.
Development of the Digital Health Guidelines for Pharmacists has been supported by the Australian Digital Health Agency. This document supersedes the My Health Record Guidelines for Pharmacists (2019), and incorporates much of this previous version. The work to update the guidelines included review by experts, stakeholder feedback, and the consensus of organisations and individuals involved. The Pharmaceutical Society of Australia thanks all those involved in the review process and, in particular, gratefully acknowledges the contribution of the following individuals and organisations.
Pharmacists are expected to exercise professional judgement when adapting the guidance provided in these guidelines to specific circumstances. The guidelines sit within a broader hierarchy of guidance underpinning and supporting the practice of pharmacists working with digital health systems (see Figure 1).
It is important to review these guidelines in conjunction with the current versions of the:
Pharmacy Board of Australia Code of Conduct for Pharmacists
National Competency Standards Framework for Pharmacists in Australia
PSA Code of Ethics for Pharmacists
• PSA Dispensing Practice Guidelines
• PSA Professional Practice Standards
• Australian Commission on Safety and Quality in Health Care National Guidelines for On-Screen Display of Medicines Information (2017)
• Australian Commission on Safety and Quality in Health Care National Guidelines for On-Screen Presentation of Discharge Summaries (2017)
The Digital Health Guideline Supplement: Real Time Prescription Monitoring (RTPM) describes the professional, regulatory and ethical obligations of community pharmacists when performing their professional clinical roles and interacting with the RTPM system.
These guidelines provide advice to pharmacists on expected professional practice when using the RTPM system, in order to provide safe supplies of monitored medicines to consumers, while continuing to meet legal and ethical obligations relating to data access and stewardship.
The guidelines should be used as a tool to support practice and professional decision making, and ensure that consumers’ needs, beliefs and preferences are met. The guidelines can be used as an educational resource to inform quality assurance processes and provide support in meeting legal requirements and ethical considerations.
The Digital Health Guideline Supplement: Real Time Prescription Monitoring (RTPM) is applicable to practising pharmacists who interact with the RTPM system.
Guidelines produced by the Pharmaceutical Society of Australia (PSA) are not definitive statements of correct procedure but represent agreements by experts in the field. The guidelines do not set a prescribed course of action or a mandatory standard to which pharmacists must adhere.
This guideline is not a technical guide on how to operate the RTPM system; rather it provides guidance on the professional and ethical behaviours for pharmacists when interacting with the RTPM in the delivery of health services.
Pharmacists are expected to exercise professional judgement when adapting the guidance provided in this guideline to specific circumstances.
This guideline sits within a broader hierarchy of guidance underpinning and supporting the practice of pharmacists working with digital health systems (Figure1).
It is important to review this guideline in conjunction with the current versions of the:
The 7th Community Pharmacy Agreement, which commenced on 1 July 2020, provides certainty, stability and flexibility for the pharmacy profession for the next five years.
HIV treatment has evolved rapidly over the past 30 years since the discovery of HIV. Since the development of zidovudine (AZT) in 1986, a large number of antiretroviral (ARV) classes have been developed, all of which aim to interrupt the HIV replication cycle at different stages. Taken in combinations of three of more medicines, treatment with ARVs can be complex, especially in instances where co-morbidities impact on treatment choice. Being confident with providing HIV ARVs for treatment will lead to a better patient experience, with these resources designed to aid in supporting the delivery of high-quality HIV treatment services within the pharmacy setting.
The PSA Vaccination Education Hub provides a variety of education, training and resources to support pharmacists in delivering vaccination services, from training to becoming a pharmacist who can administer vaccines to Continuing Professional Development, such as the PSA member-benefit Immunisation Online Refresher Course, to keep knowledge and skills up to date.
The PSA codeine resource hub will provide members with a suite of education and resources to support you through these changes, and improve the health of all Australians. We will also keep you updated on the work that PSA is doing to support members through the transition of codeine to a Prescription Only medicine.
The PSA medicinal cannabis resource hub provides members with a suite of resources to support you through these changes, to provide assistance to your customers, and as a place to find education on the latest clinical evidence.
Pharmacy Trial Program trials that were established and funded under the 6CPA will continue until the current trial end date.
The PSA provides support for pharmacists through a range of guidelines and support tools. These documents provide advice to pharmacists on process issues, desired behaviours, and how they may best fulfill their duties and responsibilities. They are not definitive statements of correct procedure.
In the spirit of reconciliation, the Pharmaceutical Society of Australia (PSA) acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today. We recognise that Aboriginal and Torres Strait Islander peoples were our first pharmacists.
© 2025 Pharmaceutical Society of Australia Ltd. All rights reserved.
